Interesting results are coming! Bexmarilimab seems to be able to improve immunotherapy. It was not yet tested on prostate cancer, but it's already commercially used to treat blood malignacies.
As single agent: faron.com/our-science/clini...
"Latest data showed a three-fold longer survival for patients achieving disease control, attributed to a bexmarilimab-induced IFN-ɣ increase leading to significant survival benefit. Patients with disease control had a median overall survival of 14.9 months, and patients without, 4.4 months."
Or as combined agent (starting soon): faron.com/our-science/clini...
Try the Clinical Trial Navigator on ChatGPT 
'Substandard' Control Arms in Clinical Trials– Practice found common in prostate cancer studies
Chemo/Pluvicto or Clinical Trial?
white-button-mushroom-clinical-trial-
Large Clinical trials show some antioxidants— dietary supplements promote tumor growth and metastasis. 
